EyePoint targets wet AMD phase III top line data mid-year while projecting cash runway into Q4 2027

Q1 2026 Management view "The start of 2026 for EyePoint was marked by a strong quarter of consistent execution as we approach a pivotal inflection point for our lead program, DURAVYU," said (President ...
Hosted on MSN

OCUL stock surges overnight ahead of crucial wet AMD data readout, Sanofi takeover buzz builds

・The company is set to release topline results from its Phase 3 superiority trial of Axpaxli in wet AMD on Tuesday. ・Ocular previously said that positive results could support a New Drug Application ...
Healthline

One Small Step: How Smart Technology Can Support Life with Wet AMD

Every day tech, like your smartphone or computer, can help manage wet AMD through built-in accessibility features such as voice commands, screen magnification, and high-contrast settings.
Business Insider

Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD

New SOL-1 post-hoc analyses presented at VBS reinforce AXPAXLI’s unmatched durability in wet AMD with sustained disease control AXPAXLI demonstrated robust CSFT control with a median time of 39 weeks ...